Hubert G Leufkens
Overview
Explore the profile of Hubert G Leufkens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
397
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Leufkens H
Pharmacoepidemiol Drug Saf
. 2019 Nov;
28(12):1562.
PMID: 31714644
No abstract available.
12.
Torre C, Cary M, Borges F, Ferreira P, Alarcao J, Leufkens H, et al.
Front Med (Lausanne)
. 2019 Aug;
6:147.
PMID: 31380375
Intensive monitoring (IM) is one of the methods of post-marketing active surveillance based upon event monitoring, which has received interest in the current medicines regulatory landscape. For a specific period...
13.
14.
Rietbergen C, Stefansdottir G, Leufkens H, Knol M, De Bruin M, Klugkist I
Front Med (Lausanne)
. 2018 Mar;
4:228.
PMID: 29520360
The current system of harm assessment of medicines has been criticized for relying on intuitive expert judgment. There is a call for more quantitative approaches and transparency in decision-making. Illustrated...
15.
Ivanovska V, Angelovska B, van Dijk L, Zdravkovska M, Leufkens H, Mantel-Teeuwisse A
Eur J Public Health
. 2018 Jan;
28(4):724-729.
PMID: 29325065
Background: Nation-wide multifaceted interventions to improve antibiotic use were undertaken in the former Yugoslav Republic of Macedonia in September 2014. This study aimed to assess the parental knowledge and attitudes...
16.
Achoki T, Kinfu Y, Masiye F, Frederix G, Hovels A, Leufkens H
J Public Health Policy
. 2017 Mar;
38(1):88-104.
PMID: 28275256
Efficiency and productivity improvement have become central in global health debates. In this study, we explored productivity change, particularly the contribution of technological progress and efficiency gains associated with improvements...
17.
Ivanovska V, Leufkens H, Rademaker C, Zisovska E, Pijnenburg M, van Dijk L, et al.
Arch Dis Child
. 2017 Jan;
102(4):352-356.
PMID: 28119403
Objective: There is a global call for formulations, which are better suited for children of different age categories and in a variety of settings. One key public health area of...
18.
Been J, Szatkowski L, van Staa T, Leufkens H, van Schayck O, Sheikh A, et al.
Sci Rep
. 2015 Oct;
5:15246.
PMID: 26463498
We investigated the association between introduction of smoke-free legislation in the UK (March 2006 for Scotland, April 2007 for Wales and Northern Ireland, and July 2007 for England) and the...
19.
Wangge G, Putzeist M, Knol M, Klungel O, Gispen-de Wied C, de Boer A, et al.
PLoS One
. 2013 Sep;
8(9):e74818.
PMID: 24040346
The active-controlled trial with a non-inferiority design has gained popularity in recent years. However, non-inferiority trials present some methodological challenges, especially in determining the non-inferiority margin. Regulatory guidelines provide some...
20.
Melchiorri D, Pani L, Gasparini P, Cossu G, Ancans J, Borg J, et al.
Nat Rev Drug Discov
. 2013 Aug;
12(9):719.
PMID: 23954897
No abstract available.